Crossmark

Correction to: Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation

Crossref DOI link: https://doi.org/10.1038/s41409-022-01606-9

Published Online: 2022-02-15

Published Print: 2022-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liang, Emily C. https://orcid.org/0000-0001-5790-4770
Chen, Connie

Lu, Rong

Mannis, Gabriel N.

Muffly, Lori https://orcid.org/0000-0002-9887-6136
License Information

Text and Data Mining valid from 2022-02-15

Version of Record valid from 2022-02-15
More Information

Article History

First Online: 15 February 2022

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below